Australia markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.63-0.18 (-2.04%)
At close: 4:00PM EDT

8.65 +0.02 (0.23%)
Pre-market: 7:09AM EDT

Full screen
Trade prices are not sourced from all markets
Previous close8.81
Open8.79
Bid0.00 x 1100
Ask0.00 x 900
Day's range8.45 - 8.91
52-week range8.06 - 33.79
Volume5,244,149
Avg. volume15,319,836
Market cap1.798B
Beta (5Y monthly)0.76
PE ratio (TTM)N/A
EPS (TTM)-1.07
Earnings date01 Mar 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.63
  • Here's the Dr. Fauci Statement That Could Mean Good News for Inovio
    Motley Fool

    Here's the Dr. Fauci Statement That Could Mean Good News for Inovio

    Inovio Pharmaceuticals (NASDAQ: INO) was among the first to start clinical trials on a coronavirus vaccine candidate. The U.S. Food and Drug Administration (FDA) last fall placed one of Inovio's vaccine trials on a partial clinical hold, and the program fell behind. Now, Inovio's candidate is in phase 2.

  • GlobeNewswire

    Lifshitz Law Firm, P.C. Announces Investigations of Inovio Pharmaceuticals, Inc. (NasdaqGS: INO), Merit Medical Systems, Inc. (NasdaqGS: MMSI), RCI Hospitality Holdings, Inc. (NasdaqGM: RICK), and Vanda Pharmaceuticals, Inc. (NasdaqGS: VNDA)

    NEW YORK, April 16, 2021 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NasdaqGS: INO) Lifshitz Law Firm, P.C. announces that on February 16, 2021, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss a putative class action complaint alleging that INO and certain officers made misleading statements about the Company’s development of a purported vaccine for the novel coronavirus, artificially inflating the Company’s share price and resulting in significant investor losses. Specifically, the Complaint alleges that Defendants capitalized on widespread COVID-19 fears by falsely claiming that Inovio had developed a vaccine for COVID-19. Plaintiffs alleged that Inovio’s stock price rose significantly in response to this disclosure, but plummeted when another company exposed Inovio’s misstatements and called for an SEC investigation into the claims. If you are an INO investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Merit Medical Systems, Inc. (NasdaqGS: MMSI) Lifshitz Law Firm, P.C. announces that on March 29, 2021, the Court issued an Order denying Defendants' Motion to Dismiss a putative class action complaint alleging that the company and certain officers made misleading statements concerning MMSI’s business and prospects. Specifically, the Complaint alleges Defendants failed to disclose that: (a) the integrations of Cianna and Vascular Insights, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during fiscal 2019; and (c) in light of the foregoing, the Company’s reported financial guidance for fiscal 2019 and 2020 was made without a reasonable basis. If you are an MMSI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. RCI Hospitality Holdings, Inc. (NasdaqGM: RICK) Lifshitz Law Firm, P.C. announces that on March 31, 2021, the Court issued an Order denying Defendants' Motion to Dismiss a putative class action complaint alleging that the Company and certain officers made misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that the Company engaged in numerous transactions with the CEO, including lending him significant sums of money; (2) that these practices were reasonably likely to lead to regulatory scrutiny of the Company; (3) that, as a result of investigations into the Company’s governance, the Company would be unable to timely file its financial statements; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis. If you are an RICK investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Vanda Pharmaceuticals, Inc. (NasdaqGS: VNDA) Lifshitz Law Firm, P.C. announces that on March 10, 2021, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss a putative class action complaint alleging that VNDA and certain officers made false statements and failed to disclose that: (1) Vanda was engaged in a fraudulent scheme in which it promoted the off-label use of Fanapt and Hetlioz; (2) Vanda was fraudulently receiving drug reimbursements from the government by abusing Medicare, Medicaid, and Tricare programs; (3) as a result of the scheme, Vanda faced legal action from the government; and (4) Vanda’s promotional materials for Fanapt and Hetlioz were false and misleading, garnering regulatory scrutiny from the U.S. Food and Drug Administration. If you are a VNDA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. ATTORNEY ADVERTISING.© 2021 Lifshitz Law Firm, P.C. The law firm responsible for this advertisement is Lifshitz Law Firm, P.C. LLP, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact: Joshua M. Lifshitz, Esq. Lifshitz Law Firm, P.C. Phone: 516-493-9780 Facsimile: 516-280-7376 Email: jml@jlclasslaw.com

  • INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern
    PR Newswire

    INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern

    INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, and cancer, today announced the results of a study focusing on the human immune responses induced by INOVIO's DNA vaccine candidate for COVID-19, INO-4800, against variants of concern. The results showed that INO-4800 induced a robust T cell response against all spike protein variants tested, which the company believes will be key in providing protection against SARS-CoV-2 variants, in addition to providing similar levels of neutralizing activity against both the UK and Brazilian variants as those against the original strain. The study, entitled "INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants," has been submitted for peer review and can be viewed at https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1.